Arvinas

Arvinas develops PROTAC therapies that degrade disease-causing proteins to treat cancer and neurodegenerative diseases.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2018
Stage of Initial Investment
Series B
Initial Investment Year
2015
Arvinas Port Co Hover Image